Platelet transfusion, also known as platelet concentrate, is used to prevent or treat bleeding in people with either a low platelet count or poor platelet function.[1] Often this occurs in people receiving cancer chemotherapy.[1] Preventive transfusion is often done in those with platelet levels of less than 10 x 109/L.[2] In those who are bleeding transfusion is usually carried out at less than 50 x 109/L.[2] Blood group matching (ABO, RhD) is typically recommended before platelets are given.[2] Unmatched platelets, however, are often used due to the unavailability of matched platelets.[3] They are given by injection into a vein.[4]
^ abcdeFisk JM, Pisciotto PT, Snyder EL, Perrota PL (2007). "Platelets and related products". In Hillyer CD, Silberstein LE, Ness PM, Anderson KC, Roback JD (eds.). Blood Banking and Transfusion Medicine: Basic Principles & Practice. Elsevier Health Sciences. pp. 308–310. ISBN978-0443069819. Archived from the original on 2017-01-12.
^Josephson CD, Castillejo MI, Grima K, Hillyer CD (February 2010). "ABO-mismatched platelet transfusions: strategies to mitigate patient exposure to naturally occurring hemolytic antibodies". Transfusion and Apheresis Science. 42 (1): 83–88. doi:10.1016/j.transci.2009.10.013. PMID20034854.
^Flagg C (2015). "Intravenous Therapy". In Linton AD (ed.). Introduction to Medical-Surgical Nursing. Elsevier Health Sciences. p. 287. ISBN978-1455776412. Archived from the original on 2017-01-12.
^World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
^World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.